C12N 2770/20051
Methods of production or purification of viral material
C12N2770/20051 (Methods of production or purification of viral material) appears on 37 US grants and 122 published applications in this corpus.
Search patents in C12N- Granted patents
- 37
- Published applications
- 122
- Assignees
- 97
- Inventors
- 380
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 1 | 1 |
| 2008 | 1 | 0 |
| 2009 | 2 | 4 |
| 2010 | 1 | 0 |
| 2011 | 3 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 3 |
| 2017 | 2 | 4 |
| 2018 | 3 | 1 |
| 2019 | 2 | 4 |
| 2020 | 2 | 2 |
| 2021 | 2 | 9 |
| 2022 | 0 | 8 |
| 2023 | 2 | 24 |
| 2024 | 4 | 25 |
| 2025 | 2 | 21 |
| 2026 | 6 | 7 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Modified S2 subunit of the coronavirus spike protein14 Apr 2026US 12,600,751 B2
- Methods and compositions for purification of trimeric fusion proteins14 Apr 2026US 12,600,761 B2Sichuan Clover Biopharmaceuticals, Inc.
- Virus-like particles7 Apr 2026US 12,594,329 B2University of Denver
- Particles, DNA and RNA27 Jan 2026US 12,533,406 B2Novoscope IP Limited
- Method for preparing corona virus-like particles and vaccine comprising the same16 Jul 2026US 2026/0201414 A1National Defense Medical University
- Crystalline-protein-based platform using viral nucleocapsid for producing target-protein-fused self-assembled nanoparticles9 Jul 2026US 2026/0193661 A1University-Industry Foundation, Yonsei University
- Multicistron expression vector for covid-19 vaccine11 Jun 2026US 2026/0159553 A1Kashiv Biosciences, LLC
- Noble cold-adapted attenuated mers-cov23 Apr 2026US 2026/0108596 A1Pioneervaccine Inc.
- Nucleic acid vaccines encapsulated with nanoaluminosilicate against middle east respiratory syndrome coronavirus (mers-cov)12 Mar 2026US 2026/0069675 A1Imam Abdulrahman Bin Faisal University
Most cited
By later US patents
- Coronavirus20US 10,130,701 B2The Pirbright Institute · 2018
- Adjuvant compositions17US 9,662,385 B2Zoetis Services LLC · 2017
- Adjuvant compositions15US 8,580,280 B2Zoetis LLC · 2013
- Highly efficient influenza matrix (M1) proteins12US 8,992,939 B2Novavax, Inc. · 2015
- Cell line for producing coronaviruses8US 7,888,102 B2Crucell Holland B. V. · 2011